Application 207777
- Type
- ANDA
- Sponsor
- GLENMARK PHARMS SA
Application Products#
Product, Drug, Ingredient table| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|
| 001 | APREPITANT | APREPITANT | CAPSULE;ORAL | 40MG | No | No |
| 002 | APREPITANT | APREPITANT | CAPSULE;ORAL | 80MG | No | No |
| 003 | APREPITANT | APREPITANT | CAPSULE;ORAL | 125MG | No | No |
NDC Listings For This Application#
NDC, Name, Nonproprietary name table| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|
| 68462-112 | Aprepitant | Aprepitant | Glenmark Pharmaceuticals Inc., USA | ANDA | Current |
| 68462-112 | Aprepitant | Aprepitant | Glenmark Pharmaceuticals Inc., USA | ANDA | Current |
| 68462-112 | Aprepitant | Aprepitant | Glenmark Pharmaceuticals Inc., USA | ANDA | Current |
| 68462-112 | Aprepitant | Aprepitant | Glenmark Pharmaceuticals Inc., USA | ANDA | Current |
| 68462-583 | Aprepitant | Aprepitant | Glenmark Pharmaceuticals Inc., USA | ANDA | Current |
| 68462-583 | Aprepitant | Aprepitant | Glenmark Pharmaceuticals Inc., USA | ANDA | Current |
| 68462-583 | Aprepitant | Aprepitant | Glenmark Pharmaceuticals Inc., USA | ANDA | Current |
| 68462-583 | Aprepitant | Aprepitant | Glenmark Pharmaceuticals Inc., USA | ANDA | Current |
| 68462-584 | Aprepitant | Aprepitant | Glenmark Pharmaceuticals Inc., USA | ANDA | Current |
| 68462-584 | Aprepitant | Aprepitant | Glenmark Pharmaceuticals Inc., USA | ANDA | Current |
| 68462-584 | Aprepitant | Aprepitant | Glenmark Pharmaceuticals Inc., USA | ANDA | Current |
| 68462-584 | Aprepitant | Aprepitant | Glenmark Pharmaceuticals Inc., USA | ANDA | Current |
| 68462-585 | Aprepitant | Aprepitant | Glenmark Pharmaceuticals Inc., USA | ANDA | Current |
| 68462-585 | Aprepitant | Aprepitant | Glenmark Pharmaceuticals Inc., USA | ANDA | Current |
| 68462-585 | Aprepitant | Aprepitant | Glenmark Pharmaceuticals Inc., USA | ANDA | Current |
| 68462-585 | Aprepitant | Aprepitant | Glenmark Pharmaceuticals Inc., USA | ANDA | Current |